Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases

被引:14
作者
Blaquiere, Nicole [1 ]
Villemure, Elisia [1 ]
Staben, Steven T. [1 ]
机构
[1] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
关键词
SMALL-MOLECULE INHIBITORS; STRUCTURE-BASED DESIGN; PROTEIN-PROTEIN INTERACTION; X-LINKED INHIBITOR; APOPTOSIS PROTEINS; STRUCTURAL BASIS; DRUG DISCOVERY; IAP ANTAGONISTS; MDM2; INHIBITOR; SMAC MIMETICS;
D O I
10.1021/acs.jmedchem.9b01451
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The ubiquitin proteasome system (UPS) presents many opportunities for pharmacological intervention. Key players in the UPS are E3 ubiquitin ligases, responsible for conjugation of ubiquitin to specific cognate substrates. Numbering more than 600 members, these ligases represent the most selective way to intervene within this physiologically important system. This Perspective highlights some of the dedicated medicinal chemistry efforts directed at inhibiting the function of specific single-protein and multicomponent RING-type E3 ubiquitin ligases. We present opportunities and challenges associated with targeting this important class of enzymes.
引用
收藏
页码:7957 / 7985
页数:29
相关论文
共 50 条
  • [21] The role of E3 ubiquitin ligases in the development and progression of glioblastoma
    Humphreys, Luke M.
    Smith, Paul
    Chen, Zhuoyao
    Fouad, Shahd
    D'Angiolella, Vincenzo
    CELL DEATH AND DIFFERENTIATION, 2021, 28 (02) : 522 - 537
  • [22] The Role of HECT E3 Ubiquitin Ligases in Colorectal Cancer
    Sun, Aiqin
    Chen, Yifei
    Tian, Xianyan
    Lin, Qiong
    BIOMEDICINES, 2023, 11 (02)
  • [23] Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
    Ye, Peng
    Chi, Xiaoxia
    Cha, Jong-Ho
    Luo, Shahang
    Yang, Guanghui
    Yan, Xiuwen
    Yang, Wen-Hao
    CELLS, 2021, 10 (12)
  • [24] Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases
    Vittal, Vinayak
    Stewart, Mikaela D.
    Brzovic, Peter S.
    Klevit, Rachel E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (35) : 21244 - 21251
  • [25] E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma
    Bielskiene, Kristina
    Bagdoniene, Lida
    Mozuraitiene, Julija
    Kazbariene, Birute
    Janulionis, Ernestas
    MEDICINA-LITHUANIA, 2015, 51 (01): : 1 - 9
  • [26] E3 ubiquitin ligases, the powerful modulator of innate antiviral immunity
    Zheng, Yi
    Gao, Chengjiang
    CELLULAR IMMUNOLOGY, 2019, 340
  • [27] The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
    Sampson, Chibuzo
    Wang, Qiuping
    Otkur, Wuxiyar
    Zhao, Haifeng
    Lu, Yun
    Liu, Xiaolong
    Piao, Hai-long
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (03):
  • [28] A General Strategy for Discovery of Inhibitors and Activators of RING and U-box E3 Ligases with Ubiquitin Variants
    Gabrielsen, Mads
    Buetow, Lori
    Nakasone, Mark A.
    Ahmed, Syed Feroj
    Sibbet, Gary J.
    Smith, Brian O.
    Zhang, Wei
    Sidhu, Sachdev S.
    Huang, Danny T.
    MOLECULAR CELL, 2017, 68 (02) : 456 - +
  • [29] Building and remodelling Cullin-RING E3 ubiquitin ligases - 'Ubiquitylation: mechanism and functions' review series
    Lydeard, John R.
    Schulman, Brenda A.
    Harper, J. Wade
    EMBO REPORTS, 2013, 14 (12) : 1050 - 1061
  • [30] The substrate binding domains of human SIAH E3 ubiquitin ligases are now crystal clear
    Zhang, Qi
    Wang, Zhongduo
    Hou, Feng
    Harding, Rachel
    Huang, Xinyi
    Dong, Aiping
    Walker, John R.
    Tong, Yufeng
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2017, 1861 (01): : 3095 - 3105